Clinical Trial Update: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus [Phase 2, Phase 3]

View source ↗

Summary

Biogen is conducting a two-part Phase 2/3 trial evaluating litifilimab (BIIB059) for adults with active cutaneous lupus erythematosus; the study is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus
• Subacute Cutaneous Lupus Erythematosus

Drugs mentioned

• Litifilimab (litifilimab)

Snippet

Sponsor: Biogen | Conditions: Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | Phase 2, Phase 3 | Status: RECRUITING